Some patients increase adherence due to lower cost and improved accessibility
Personalized Weight Loss Plans for Real, Lasting Results At Aesthetics at Southern, we know that achieving and maintaining a healthy weight isnt one-size-fits-all
Writing down details can make the conversation easier and more productive
While Novo Nordisk and Eli Lilly both have promising GLP-1 pipelines and anticipate multiple drug launches over the next five years, several other big pharma companies are also investing heavily in GLP-1 drugs in a bid to grab a slice of the pie, primarily through the acquisition of biotech developers [FIGURE THREE]
As we navigate this evolving landscape, its evident that customized solutions, patient-centered approaches, and ongoing dialogue will remain at the heart of decisions that have the potential to reshape how we address weight management and its associated health outcome
doi: 10.1210/endrev/bnaa016 [DOI] [PMC free article] [PubMed] [Google Scholar] 110